高脂血症时血清二乙基对硝基苯磷酸酯酶活性的变化

目的 :研究tritonWR 13 3 9致小鼠高脂血症时血清二乙基对硝基苯磷酸酯酶 (ParaoxonaseI ,PON 1)活性的变化及PON 1活性与血浆脂质含量之间的关系。方法 :在小鼠尾静脉注射tritonWR13 3 9后的 3h ,6h ,12h ,2 4h ,48h ,72h ,眼球摘除术取血 ,用酶标法测定小鼠血浆总胆固醇 (TC) ,甘油三酯 (TG ) ,高密度脂蛋白 -胆固醇 (HDL -C) ,载脂蛋白AI (ApoAI) ,载脂蛋白B (ApoB含量 ) ,并计算出ApoAI/ApoB ,HDL -C/TC比值 ,用分光光度计法测定PONI活性。结果 :TritonWR 13 3 9尾静脉注射后 3h ,小鼠血浆TC和TG含量即急剧增高 ,与对照组相比 ,P <0 .0 1,分别在注射后 2 4h和 3h达到峰值 ,随后逐渐下降 ,其中血浆TG含量在注射后 48h即恢复正常水平。tritonWR13 3 9尾静脉注射后 3h ,小鼠血浆HDL -C和ApoB含量急剧增高 ,与对照组相比 ,P <0 .0 5,分别在注射后 2 4h和 6h达到峰值 ,随后逐渐下降 ,分别在注射后 48h和 72h恢复正常水平。tritonWR13 3 9尾静脉注射后 3h ,小鼠血浆ApoAI含量即急剧降低 ,与对照组相比 ,P <0 .0 5,随后逐渐增高 ,在注射后 6h即恢复正常水平。tritonWR 13 3 9尾静脉注射后 3h ,小鼠血浆ApoAI/ApoB和HDL-C/TC比值减少 ,与对照组相比 ,P <0 .0 1,随后逐渐增高 ,其中ApoAI/ApoB比值在 72h恢复     

伊贝沙坦与苯那普利、卡托普利对高血压肾病患者尿总蛋白排泄量及内生肌酐清除率影响的比较

目的 :观察伊贝沙坦 (irbesartan)和血管紧张素转换酶抑制剂对高血压肾病患者尿总蛋白排泄量 (UPER)与内生肌酐清除率 (Ccr)的影响 ,比较不同的血管紧张素拮抗剂上述作用的差别。方法 :以序贯试验的方法选择了用伊贝沙坦或苯那普利中卡托普利治疗的高血压肾病患者共 6 6例 ,分为人数相等的 3组 ,进行了治疗前、后 3组间降压效果、UPER、Ccr的比较。结果 :伊贝沙坦了压效果与苯那普利、卡托普利相似 ,但伊贝沙坦对UPER、Ccr的效果优于苯那普利和卡托普利 ,3组比较有统计学的差异 (P <0 .0 1)。伊贝沙坦组未见于干咳现象 ,而苯那普利组及卡托普利组分别干咳发生率分别为 4 .5 %和 13.6 %。结论 :肾功能轻、中度损害的高血压肾病患者服用伊贝沙坦 ,不仅可有效降低血压 ,还可以更好地降低UPER ,提高Ccr。     

以病人选择医生为契机 全力推进人事分配制度改革

介绍了邯郸市中心医院在病人选医生中,努力完善制度,提高素质,深化内容,并以此为突破口,建立了灵活、高效的人事分配制度.用较为低廉的医疗费用,为人民群众提供了较好的医疗服务.     

OSAS患者循环ICAM-1,VCAM-1及L-选择素水平与心血管疾病的研究

目的 :探讨阻塞性睡眠呼吸暂停综合征 (OSAS)患者循环细胞间黏附分子 - 1(intercellularadhesionmolecule 1,ICAM - 1)、血管细胞黏附分子 - 1(vasculaecelladhesionmolecule 1,VCAM -l)及L -选择素 (L -selection)水平及与心血管疾病的相关性。方法 :选取OSAS患者 12例 (男性 9例 ,女性 3例 ,平均年龄 5 1.6±4 .8岁 )及 12例年龄相匹配的健康对照者。采用ELISA法检测OSAS患者入睡前、睡醒后血浆ICAM - 1、VCAM - 1及L -选择素水平 ,并与正常对照组比较。结果 :OSAS患者入睡前ICAM - 1,VCAM - 1及L -选择素水平较正常对照组升高 (ICAM - 1:4 0 2 .8± 4 8.2vs 2 0 8.4± 5 6 ,P <0 .0 5 ;VCAM - 1:814± 88.9vs 5 82±4 4 .5 ,P <0 .0 5 ;L -选择素 :1390 .4± 76 .8vs 10 4 4 .3± 80 .2 ,P <0 .0 1) ,睡醒后ICAM - 1及L -选择素水平较正常对照组明显升高 (ICAM - 1:395± 4 5vs 2 0 5± 5 0 ,P <0 .0 5 ;L -选择素 :114 3.5± 196 .2vs 10 2 5 .6±5 0 .3,(P <0 .0 5 )。结论 :OSAS所致的低氧血症激活了循环黏附分子 ,参与了心血管疾病的发生与发展。     

OVERHEATING IN BED AS AN IMPORTANT FACTOR IN MANY COMMON DERMATOSES

Background. Extensive questioning of patients with a wide variety of skin disorders led to the impression that nocturnal overheating was probably an important factor in the initiation and the perpetuation of many skin disorders. Methods. In order to test the hypothesis, 12 “clean-skinned” subjects (6M/6F) aged 18 to 45 years were monitored electronically every 30 seconds during an 8 hour sleep period (2300 to 0700 hours), sleeping under a standard 10 tog duvet. Results. All the subjects were too hot by 3 to 4°C. All showed changes in their EEG patterns with reduced REM sleep, increased awakenings, and all showed changes in their sleep stage patterns. In addition, they all showed evidence of increased sweating in the “heat-sink” area. Conclusions. The mechanisms where by such changes could be implicated in the precipitation and perpetuation of skin disease are discussed. “Lifestyle” modification as a very effective, noninvasive, therapeutic regime is recommended. Further research along these lines would probably be very valuable and instructive.     

抗击"非典"为改善医患关系提供了新契机

文章通过分析在抗击“非典”特殊时期医务人员为科学、为病人的献身精神，以及广大人民对医疗高风险、高费用的全面了解，论证抗击“非典”为病人重新认识医务人员，促进医患沟通，改善日趋紧张的医患关系提供了新契机。     

Treatment of refractoriness to platelet transfusion by protein A column therapy

Ten thrombocytopenic patients (platelets < 10–24 × 10(9)/L) who were refractory to platelet transfusion were investigated for their responsiveness to staphylococcal protein A column therapy. Nine patients had previously been treated with steroids, intravenous immune globulin, and/or other forms of immunosuppressive therapy without improvement in their transfusion response. All patients were receiving multiple platelet transfusions without achieving 1-hour corrected count increments (CCIs) > or = 7500. Eight patients had antibodies that reacted with platelets and were directed against HLA class I antigens, ABO antigens, and/or platelet-specific alloantigens. Plasma (500-2000 mL) from each patient was passed over a protein A silica gel column and then returned to the patient. Patients received from 1 to 14 treatments. A positive response to protein A therapy was defined as at least a doubling of the pretreatment platelet count and/or two successive 10- to 120-minute posttransfusion CCIs > or = 7500. Following plasma treatments, 6 of 10 patients responded with daily platelet counts that averaged 48 +/− 11 × 10(9) per L as compared with counts of 16 +/− 7 × 10(9) per L (p < 0.0005) before treatment. Posttransfusion CCI values determined in four of these patients averaged 2480 +/− 810 and 10,010 +/− 3540 (p < 0.005) before and after treatment, respectively. In contrast, among the four unresponsive patients, platelet counts averaged 10 +/− 9 and 13 +/− 10 × 10(9) per L (p = NS), respectively, while posttransfusion CCIs were 700 +/− 1410 and 1520 +/− 2460 (p = NS), respectively.(ABSTRACT TRUNCATED AT 250 WORDS)